Literature DB >> 20553920

Heart rate correction of the QT duration in rats.

Jana Kmecova1, Jan Klimas.   

Abstract

Duration of heart rate corrected QT interval (QTc) is a crucial and critical factor in the assessment of repolarization changes considering safety of drugs and cardiac disorders. In rats, a validated approach to QT correction is lacking. In this study, we tested the normalization of QTc using normalization factor according to rat's cardiac cycle length (RR). Standard 12-lead ECG was measured in anesthetized rats at basal conditions and at various pharmacological conditions such as beta-adrenergic stimulation with isoproterenol or medication with clarithromycin (single- or repeated dosing for seven days), bisoprolol or ivabradine. For QT correction, standard Bazett's formula (QTc-B=QT/(RR)(1/2)) and Bazett's formula normalized to average rat RR (QTc(n)-B=QT/(RR/f)(1/2), f=150ms) were compared. Duration of QT showed a positive correlation with RR duration (Pearson r=0.7645, P<0.001). Calculated QTc-B gave 2-2.5 fold of values of uncorrected QT, whereas values of normalized QTc(n)-B were in the physiological range. QTc(n)-B was unrelated to RR (Pearson r=0.1122, not significant) but the relationship between QTc(n)-B and QT remained preserved (Pearson r=0.7216, P<0.001). Both single and repeated administration of clarithromycin prolonged QT as compared to the controls but a significant dose-dependent difference between clarithromycin applications was revealed only when QTc(n)-B was used. Beta-adrenergic stimulation with isoproterenol prolonged, while beta-blockade with bisoprolol shortened QTc(n)-B. Ivabradine dose-dependently induced bradycardia without altering QT. However, QTc(n)-B showed false positive shortening at sustained bradycardia. Therefore, adjusted formula for QTc(n)-B is suitable for QT correction in rats but its use should be considered carefully in case of very low heart rate. Copyright (c) 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20553920     DOI: 10.1016/j.ejphar.2010.05.038

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  49 in total

1.  Upregulation of SERCA2a following short-term ACE inhibition (by enalaprilat) alters contractile performance and arrhythmogenicity of healthy myocardium in rat.

Authors:  Marek Matus; Dana Kucerova; Peter Kruzliak; Adriana Adameova; Gabriel Doka; Katarina Turcekova; Jana Kmecova; Jan Kyselovic; Peter Krenek; Uwe Kirchhefer; Frank U Mueller; Peter Boknik; Jan Klimas
Journal:  Mol Cell Biochem       Date:  2015-02-08       Impact factor: 3.396

Review 2.  Modulation of the QT interval duration in hypertension with antihypertensive treatment.

Authors:  Jan Klimas; Peter Kruzliak; Simon W Rabkin
Journal:  Hypertens Res       Date:  2015-03-19       Impact factor: 3.872

3.  Analysis of decreases in systemic arterial pressure and heart rate in response to the hydrogen sulfide donor sodium sulfide.

Authors:  Kevin W Swan; Bryant M Song; Allen L Chen; Travis J Chen; Ryan A Chan; Bradley T Guidry; Prasad V G Katakam; Edmund K Kerut; Thomas D Giles; Philip J Kadowitz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-06-30       Impact factor: 4.733

4.  Antimalarial agents against both sexual and asexual parasites stages: structure-activity relationships and biological studies of the Malaria Box compound 1-[5-(4-bromo-2-chlorophenyl)furan-2-yl]-N-[(piperidin-4-yl)methyl]methanamine (MMV019918) and analogues.

Authors:  Alessandra Vallone; Sarah D'Alessandro; Simone Brogi; Margherita Brindisi; Giulia Chemi; Gloria Alfano; Stefania Lamponi; Soon Goo Lee; Joseph M Jez; Karin J M Koolen; Koen J Dechering; Simona Saponara; Fabio Fusi; Beatrice Gorelli; Donatella Taramelli; Silvia Parapini; Reto Caldelari; Giuseppe Campiani; Sandra Gemma; Stefania Butini
Journal:  Eur J Med Chem       Date:  2018-03-10       Impact factor: 6.514

5.  Evidence for cardiotoxicity associated with sertraline in rats.

Authors:  Sinem Ilgin; Volkan Kilic; Merve Baysal; Gozde Aydogan-Kilic; Seyda Ucarcan; Begum Dermenci; Ozlem Atli
Journal:  Toxicol Res (Camb)       Date:  2018-04-06       Impact factor: 3.524

6.  Reverse electrical remodeling following pressure unloading in a rat model of hypertension-induced left ventricular myocardial hypertrophy.

Authors:  Mihály Ruppert; Sevil Korkmaz-Icöz; Shiliang Li; Béla Merkely; Matthias Karck; Tamás Radovits; Gábor Szabó
Journal:  Hypertens Res       Date:  2017-01-26       Impact factor: 3.872

7.  Superiority of zinc complex of acetylsalicylic acid to acetylsalicylic acid in preventing postischemic myocardial dysfunction.

Authors:  Sevil Korkmaz; Ayhan Atmanli; Shiliang Li; Tamás Radovits; Peter Hegedűs; Enikő Barnucz; Kristóf Hirschberg; Sivakkanan Loganathan; Yutaka Yoshikawa; Hiroyuki Yasui; Matthias Karck; Gábor Szabó
Journal:  Exp Biol Med (Maywood)       Date:  2015-02-09

8.  Administration of zinc complex of acetylsalicylic acid after the onset of myocardial injury protects the heart by upregulation of antioxidant enzymes.

Authors:  Sevil Korkmaz-Icöz; Ayhan Atmanli; Tamás Radovits; Shiliang Li; Peter Hegedüs; Mihály Ruppert; Paige Brlecic; Yutaka Yoshikawa; Hiroyuki Yasui; Matthias Karck; Gábor Szabó
Journal:  J Physiol Sci       Date:  2015-10-23       Impact factor: 2.781

9.  Unbalanced upregulation of ryanodine receptor 2 plays a particular role in early development of daunorubicin cardiomyopathy.

Authors:  Dana Kucerova; Gabriel Doka; Peter Kruzliak; Katarina Turcekova; Jana Kmecova; Zuzana Brnoliakova; Jan Kyselovic; Uwe Kirchhefer; Frank U Müller; Peter Krenek; Peter Boknik; Jan Klimas
Journal:  Am J Transl Res       Date:  2015-07-15       Impact factor: 4.060

10.  In vivo arrhythmogenicity of the marine biotoxin azaspiracid-2 in rats.

Authors:  Sara F Ferreiro; Natalia Vilariño; Cristina Carrera; M Carmen Louzao; Germán Santamarina; Antonio G Cantalapiedra; Laura P Rodríguez; J Manuel Cifuentes; Andrés C Vieira; K C Nicolaou; Michael O Frederick; Luis M Botana
Journal:  Arch Toxicol       Date:  2013-08-11       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.